Antidiabetic and hypocholesterolaemic effects of fenugreek

Molham Al-Habori, Amala Soumyanath

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

The seeds of Trigonella foenum graecum (fenugreek) have been reported to have antidiabetic and hypocholesterolaemic properties in both animal models and humans. Activity has been attributed largely to fenugreek's saponin and high fibre content, and is probably not related to its major alkaloid trigonelline. Antihyperglycaemic effects have been linked to delayed gastric emptying caused by the fibre content, and to (unidentified) components that inhibit carbohydrate digestive enzymes. Fenugreek administration may increase plasma insulin levels in vivo. Its major free amino acid, 4- hydroxyisoleucine, stimulates insulin secretion from perfused pancreas in vitro. The hypocholesterolaemic effect has been attributed to increased conversion of hepatic cholesterol to bile salts due to loss, in the faeces, of complexes of these substances with fenugreek fibre and saponins. Fenugreek treatment selectively reduces the LDL and VLDL fractions of total cholesterol, and HDL-cholesterol has also been reported to increase in alloxan-induced diabetic rats and type II diabetic individuals following treatment with fenugreek. Fenugreek administration has not been reported to cause any toxicological effects. Its regular consumption may therefore be beneficial in the management of diabetes and the prevention of atherosclerosis and coronary heart disease.

Original languageEnglish (US)
Pages (from-to)233-242
Number of pages10
JournalPhytotherapy Research
Volume12
Issue number4
DOIs
StatePublished - Jun 1998
Externally publishedYes

Fingerprint

Trigonella
Hypoglycemic Agents
Saponins
Fibers
Insulin
Alloxan
Cholesterol
Medical problems
Bile Acids and Salts
Alkaloids
HDL Cholesterol
Seed
Rats
Animals
Carbohydrates
Plasmas
Amino Acids
Enzymes
Gastric Emptying
Feces

Keywords

  • Antidiabetic
  • Fenugreek
  • Fibre
  • Hypocholesterolaemic
  • Insulin
  • Saponins

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Antidiabetic and hypocholesterolaemic effects of fenugreek. / Al-Habori, Molham; Soumyanath, Amala.

In: Phytotherapy Research, Vol. 12, No. 4, 06.1998, p. 233-242.

Research output: Contribution to journalArticle

@article{c8d0b4ab8319414abbacb90fe1559327,
title = "Antidiabetic and hypocholesterolaemic effects of fenugreek",
abstract = "The seeds of Trigonella foenum graecum (fenugreek) have been reported to have antidiabetic and hypocholesterolaemic properties in both animal models and humans. Activity has been attributed largely to fenugreek's saponin and high fibre content, and is probably not related to its major alkaloid trigonelline. Antihyperglycaemic effects have been linked to delayed gastric emptying caused by the fibre content, and to (unidentified) components that inhibit carbohydrate digestive enzymes. Fenugreek administration may increase plasma insulin levels in vivo. Its major free amino acid, 4- hydroxyisoleucine, stimulates insulin secretion from perfused pancreas in vitro. The hypocholesterolaemic effect has been attributed to increased conversion of hepatic cholesterol to bile salts due to loss, in the faeces, of complexes of these substances with fenugreek fibre and saponins. Fenugreek treatment selectively reduces the LDL and VLDL fractions of total cholesterol, and HDL-cholesterol has also been reported to increase in alloxan-induced diabetic rats and type II diabetic individuals following treatment with fenugreek. Fenugreek administration has not been reported to cause any toxicological effects. Its regular consumption may therefore be beneficial in the management of diabetes and the prevention of atherosclerosis and coronary heart disease.",
keywords = "Antidiabetic, Fenugreek, Fibre, Hypocholesterolaemic, Insulin, Saponins",
author = "Molham Al-Habori and Amala Soumyanath",
year = "1998",
month = "6",
doi = "10.1002/(SICI)1099-1573(199806)12:4<233::AID-PTR294>3.0.CO;2-V",
language = "English (US)",
volume = "12",
pages = "233--242",
journal = "Phytotherapy Research",
issn = "0951-418X",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Antidiabetic and hypocholesterolaemic effects of fenugreek

AU - Al-Habori, Molham

AU - Soumyanath, Amala

PY - 1998/6

Y1 - 1998/6

N2 - The seeds of Trigonella foenum graecum (fenugreek) have been reported to have antidiabetic and hypocholesterolaemic properties in both animal models and humans. Activity has been attributed largely to fenugreek's saponin and high fibre content, and is probably not related to its major alkaloid trigonelline. Antihyperglycaemic effects have been linked to delayed gastric emptying caused by the fibre content, and to (unidentified) components that inhibit carbohydrate digestive enzymes. Fenugreek administration may increase plasma insulin levels in vivo. Its major free amino acid, 4- hydroxyisoleucine, stimulates insulin secretion from perfused pancreas in vitro. The hypocholesterolaemic effect has been attributed to increased conversion of hepatic cholesterol to bile salts due to loss, in the faeces, of complexes of these substances with fenugreek fibre and saponins. Fenugreek treatment selectively reduces the LDL and VLDL fractions of total cholesterol, and HDL-cholesterol has also been reported to increase in alloxan-induced diabetic rats and type II diabetic individuals following treatment with fenugreek. Fenugreek administration has not been reported to cause any toxicological effects. Its regular consumption may therefore be beneficial in the management of diabetes and the prevention of atherosclerosis and coronary heart disease.

AB - The seeds of Trigonella foenum graecum (fenugreek) have been reported to have antidiabetic and hypocholesterolaemic properties in both animal models and humans. Activity has been attributed largely to fenugreek's saponin and high fibre content, and is probably not related to its major alkaloid trigonelline. Antihyperglycaemic effects have been linked to delayed gastric emptying caused by the fibre content, and to (unidentified) components that inhibit carbohydrate digestive enzymes. Fenugreek administration may increase plasma insulin levels in vivo. Its major free amino acid, 4- hydroxyisoleucine, stimulates insulin secretion from perfused pancreas in vitro. The hypocholesterolaemic effect has been attributed to increased conversion of hepatic cholesterol to bile salts due to loss, in the faeces, of complexes of these substances with fenugreek fibre and saponins. Fenugreek treatment selectively reduces the LDL and VLDL fractions of total cholesterol, and HDL-cholesterol has also been reported to increase in alloxan-induced diabetic rats and type II diabetic individuals following treatment with fenugreek. Fenugreek administration has not been reported to cause any toxicological effects. Its regular consumption may therefore be beneficial in the management of diabetes and the prevention of atherosclerosis and coronary heart disease.

KW - Antidiabetic

KW - Fenugreek

KW - Fibre

KW - Hypocholesterolaemic

KW - Insulin

KW - Saponins

UR - http://www.scopus.com/inward/record.url?scp=0031856305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031856305&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-1573(199806)12:4<233::AID-PTR294>3.0.CO;2-V

DO - 10.1002/(SICI)1099-1573(199806)12:4<233::AID-PTR294>3.0.CO;2-V

M3 - Article

AN - SCOPUS:0031856305

VL - 12

SP - 233

EP - 242

JO - Phytotherapy Research

JF - Phytotherapy Research

SN - 0951-418X

IS - 4

ER -